miR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway

被引:41
|
作者
Che, Shusheng [1 ]
Sun, Tingting [2 ]
Wang, Jianpeng [1 ]
Jiao, Yingbin [1 ]
Wang, Chao [1 ]
Meng, Qinghai [1 ]
Qi, Weiguo [1 ]
Yan, Zhiyong [1 ]
机构
[1] Qingdao Univ, Dept Neurosurg, Affiliated Hosp, Qingdao 266003, Shandong, Peoples R China
[2] Qingdao Municipal Hosp, Intens Care Unit, Qingdao 266011, Shandong, Peoples R China
关键词
miR-30; SOCS3; Jak/STAT3; Glioma; GSC; TRANSCRIPTION; 3; GLIOBLASTOMA; CANCER; STAT3; CYTOKINE; EXPRESSION; PROLIFERATION; TRANSDUCER; INHIBITORS; MICRORNAS;
D O I
10.1007/s13277-015-3400-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Malignant glioma is the most common intracranial tumor with poor prognosis. It is well believed that glioma stem cells (GSCs) are responsible for the initiation and progression of glioma. Janus kinase/signal transducer and activator of transcription (Jak/STAT3) pathway plays a key role in the functions of GSCs. However, the regulatory mechanism of Jak/STAT3 pathway has not been completely elucidated. This study employed multidisciplinary approaches to investigate the upstream regulators of Jak/STAT3 signaling in GSCs. miR-30 was found to be overexpressed in the GSCs derived from U-87 MG and primary glioma cells, compared with non-stem-cell-like glioma cells and normal cells. Downregulation of miR-30 was able to suppress Jak/STAT3 pathway and reduce the tumorigenecity of GSCs. miR-30 decreased the expression of suppressor of cytokine signaling 3 (SOCS3) expression by targeting 3'UTR of its mRNA. The silencing of SOCS3 abolished the effect of miR-30 downregulation on GSCs. Collectively, there is a regulatory pathway consisting of miR-30, SOCS3, and Jak/STAT3 in GSCs, and targeting this pathway may be a promising strategy to treat glioma.
引用
收藏
页码:6805 / 6811
页数:7
相关论文
共 50 条
  • [21] The NEK1 gene regulates the JAK-STAT signaling pathway and promotes the proliferation of glioma cells
    Xia, Kailai
    Liu, Yan
    Tang, Hua
    Han, Jing
    Guan, Yuhua
    Zheng, Gang
    Chen, Shaojun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (12): : 9353 - 9362
  • [22] CTR9-mediated JAK2/STAT3 pathway promotes the proliferation, migration, and invasion of human glioma cells
    Xu, Yang
    Chen, Jiaguo
    He, Gao
    Zhang, Yuhai
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (09)
  • [23] JAK/STAT3 signaling pathway in mantle cell lymphoma (MCL)
    Yared, MA
    Medeiros, LJ
    Khoury, JD
    Rassidakis, GZ
    Leventaki, V
    Lai, R
    MODERN PATHOLOGY, 2003, 16 (01) : 260A - 261A
  • [24] The role of the JAK/STAT3 signaling pathway in acquired corneal diseases
    Song, Dongjie
    Yang, Qianjie
    Li, Xiang
    Chen, Kuangqi
    Tong, Jianping
    Shen, Ye
    EXPERIMENTAL EYE RESEARCH, 2024, 238
  • [25] JAK/Stat3 signaling pathway modulates human megakaryocytic differentiation
    Liao Hui-Fen
    Peng, Hsuan-Yu
    Chen, Yu-Jen
    CANCER RESEARCH, 2011, 71
  • [26] Overexpression of miR-4443 promotes the resistance of non-small cell lung cancer cells to epirubicin by targeting INPP4A and regulating the activation of JAK2/STAT3 pathway
    Zhang, Weiguo
    Qiao, Bin
    Fan, Junli
    PHARMAZIE, 2018, 73 (07): : 386 - 392
  • [27] TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway
    Hou, Jianbing
    Lv, Ailing
    Deng, Qing
    Zhang, Guanghui
    Hu, Xiaosong
    Cui, Hongjuan
    ONCOLOGY REPORTS, 2019, 41 (02) : 753 - 764
  • [28] The Interaction Between Autophagy and JAK/STAT3 Signaling Pathway in Tumors
    Xu, Jiangyan
    Zhang, Jinrong
    Mao, Qi-Fen
    Wu, Jian
    Wang, Yuan
    FRONTIERS IN GENETICS, 2022, 13
  • [29] JAK/STAT3 signaling pathway in mantle cell lymphoma (MCL)
    Yared, MA
    Medeiros, LJ
    Khoury, JD
    Rassidakis, GZ
    Leventaki, V
    Lai, R
    LABORATORY INVESTIGATION, 2003, 83 (01) : 260A - 261A
  • [30] TIAM2 promotes proliferation and invasion of osteosarcoma cells by activating the JAK2/STAT3 signaling pathway
    Cheng, Shaohua
    Huang, Xinghan
    Guo, Weichun
    JOURNAL OF BONE ONCOLOGY, 2022, 37